Company intelligence / Profile preview

Southern XP IP

Victoria, Australia

Ownership: Private
Development stage: Other

Overview

Southern XP IP commercially distributes and licenses approved pharmaceuticals such as midodrine hydrochloride (ADRA1 agonist) for hypotension and amikacin sulfate (30S ribosomal subunit inhibitor) for nontuberculous mycobacterium infections. These drugs have prior first approvals in Japan (midodrine hydrochloride) and China (amikacin sulfate).

Therapeutic areas: Infectious DiseasesCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Takeda Pharmaceutical (distribution/licensing for midodrine hydrochloride)

Beyond the preview

Go deeper on Southern XP IP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Southern XP IP.

Explore the full profile